Fosamax and Osteonecrosis of the Jaw: Understanding the Link and Risk Factors

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Awareness to Targeted Pharmaceutical Risk

The legacy of general health and science information has long provided a foundation for understanding broad public health risks, from infectious disease outbreaks to chronic condition management. This heritage emphasizes the importance of evidence-based awareness and preventive measures across diverse populations. Within this context, the transition to examining specific pharmaceutical exposures and their potential adverse effects becomes a natural progression. The focus shifts from population-level health dynamics to individual risk factors associated with long-term medication use. In mass production environments, where workers may encounter or handle pharmaceutical compounds, the concern extends beyond clinical prescribing to occupational exposure scenarios. This pivot acknowledges that understanding drug safety profiles, such as those related to bisphosphonate therapies, requires careful consideration of both therapeutic and unintended exposure pathways. The bridge from general health literacy to occupational risk assessment underscores the need for rigorous monitoring and protective protocols in manufacturing settings, where sustained contact with active pharmaceutical ingredients could pose distinct health considerations. This transition maintains a neutral, evidence-informed perspective without delving into specific disease mechanisms or citing external studies, instead focusing on the logical extension from broad health knowledge to targeted exposure concerns in industrial contexts.

Fosamax and Osteonecrosis of the Jaw: An Overview

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its pharmacological action involves inhibiting bone resorption, which increases bone mass and reduces fracture incidence. However, a recognized adverse effect associated with bisphosphonate use, including Fosamax, is osteonecrosis of the jaw (ONJ). ONJ is a condition characterized by exposed, non-healing bone in the jaw, which can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The clinical presentation often involves pain, swelling, and exposed bone in the oral cavity, with diagnosis typically based on clinical examination and imaging. The condition has been reported in patients taking bisphosphonates, including Fosamax and Fosamax Plus D (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Mechanisms and Risk Factors for ONJ

Mechanistic pathways linking Fosamax to ONJ are not fully elucidated, but research suggests that bisphosphonates accumulate in the jawbone and alter bone remodeling. A multiscale characterization of jawbone provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077). This indicates that the unique structure and physiology of the jawbone may make it particularly susceptible to the effects of bisphosphonates, potentially leading to impaired healing and necrosis. Risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates. For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Timeline, Incidence, and Warning Adequacy

Regarding the timeline between exposure and documented harm, the time to onset of symptoms varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug, but a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate. In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This suggests that while ONJ is a recognized risk, its incidence in clinical trials was low and not significantly different from placebo. Adequacy of warnings regarding Fosamax and ONJ is addressed in the prescribing information. The label includes a specific warning under section 5.4 "Osteonecrosis of the Jaw," which describes the condition, associated risk factors, and recommendations for management (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56; https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The label also notes that the optimal duration of use has not been determined, and for patients at low-risk for fracture, consider drug discontinuation after 3 to 5 years of use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This provides guidance for clinicians to weigh benefits and risks.

Causation Evidence and Epidemiological Data

Causation-related considerations for affected patients involve understanding the relationship between Fosamax exposure and ONJ development. A cohort study among female patients treated for osteoporosis in the United Kingdom Clinical Practice Research Datalink found that ONJ risk was threefold higher after 2-3 years of treatment and eightfold after 10 years compared with past use (https://pubmed.ncbi.nlm.nih.gov/39400702). Absolute risks remained low, approximately 0.05% after 5 years, and diminished after discontinuation. This data supports a causal association, with risk increasing with longer exposure duration. However, the low absolute risk indicates that ONJ is a rare event in osteoporosis patients. In summary, Fosamax is associated with an increased risk of ONJ, particularly with longer duration of use and in the presence of other risk factors such as invasive dental procedures. The prescribing information provides warnings and recommendations for risk mitigation, including consideration of drug discontinuation for low-risk patients after 3-5 years. Mechanistic studies suggest jawbone-specific responses to bisphosphonates contribute to ONJ development. For affected patients, the timeline from exposure to harm can range from days to months, and risk diminishes after stopping the drug. Causation is supported by epidemiological data showing a dose-response relationship, though absolute risk remains low.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Fosamax and how does it work?

Fosamax (alendronate) is a bisphosphonate medication used to treat and prevent osteoporosis by inhibiting bone resorption, thereby increasing bone mass and reducing fracture risk. It is also used for Paget's disease of bone and glucocorticoid-induced osteoporosis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What is osteonecrosis of the jaw (ONJ) and how is it linked to Fosamax?

ONJ is a condition of exposed, non-healing bone in the jaw, often associated with dental procedures or infection. Fosamax and other bisphosphonates can increase the risk of ONJ, especially with long-term use. The exact mechanism is not fully understood, but bisphosphonates accumulate in the jawbone and alter bone remodeling (https://pubmed.ncbi.nlm.nih.gov/40345077).

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures (tooth extraction, implants), cancer, concomitant therapies (chemotherapy, corticosteroids), poor oral hygiene, pre-existing dental disease, anemia, coagulopathy, infection, and ill-fitting dentures. The risk increases with longer duration of Fosamax use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How common is ONJ in patients taking Fosamax for osteoporosis?

ONJ is rare in osteoporosis patients. A cohort study found absolute risk about 0.05% after 5 years of treatment. However, risk increases with duration: threefold higher after 2-3 years and eightfold after 10 years compared to past use (https://pubmed.ncbi.nlm.nih.gov/39400702).

What does the Fosamax label say about ONJ?

The label includes a specific warning (Section 5.4) describing ONJ, risk factors, and management recommendations. It advises considering drug discontinuation after 3-5 years for low-risk patients and notes that stopping the drug may reduce ONJ risk before invasive dental procedures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.